In this month’s “Hot Topic,” Vlad Vasile, M.D., Ph.D., reviews ceramides and their atherosclerotic risk through defining ceramides, talking about when they should be tested for and touch on the topic of ceramides in primary prevention.
In this month’s “Hot Topic,” Julia Lehman, M.D., will discuss autoimmune bullous dermatoses, the rare category of blistering skin diseases that are caused by the development of autoantibodies against various constitutive parts of the epidermis or dermal-epidermal junction.
In this month's "Hot Topic," Jess Peterson, M.D., discusses changes to Mayo Clinic Laboratories’ hematology FISH menu to increase awareness, provide reasoning, and highlight some of the great things that are coming.
In this month’s “Hot Topic,” Anja Roden, M.D., discusses new entities and changes of terminology in the 2021 World Health Organization (WHO) classification of lung tumors as well as the nomenclature in small biopsies.
In this month’s “Hot Topic,” Elitza Theel, Ph.D., discusses the modified two-tiered testing algorithm for Lyme disease entirely based on enzyme immunoassays (EIA).
In this month’s “Hot Topic,” Brad Karon, M.D., Ph.D., reviews the results of a study that Mayo Clinic recently published comparing four different rapid antigen tests for novel coronavirus.
In this month’s “Hot Topic,” Julia Lehman, M.D., discusses a recent change to the direct immunofluorescence assay, specifically the addition of the IgG4 conjugate.
In this month’s “Hot Topic,” Sean Pittock, M.D., explains Neuromyelitis Optica Spectrum Disorder (NMOSD) and the critical importance of a sensitive and specific AQP4-IgG laboratory test for early diagnosis and treatment.
This is a 6-part series describing the products and clinical tools of a laboratory quality improvement project called Region 4 Stork, or R4S.
In this month’s “Hot Topic,” Joaquín J. García, M.D., highlights the value of Mayo Clinic’s Pathology Consultation practice and provides guidance for optimizing the consult experience with Mayo Clinic Laboratories.
In this month’s “Hot Topic,” Andrew McKeon, M.B., B.Ch., M.D., reviews the use of neurological phenotype-based evaluations, the move away from the paraneoplastic evaluation, and upcoming changes to test profiles.
In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the use of qualitative urine screening assays and quantitative confirmatory testing to determine compliance in pain management patients.
In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the high-resolution targeted stimulant and PCP screening test from Mayo Clinic Laboratories, which offers sensitivity and specificity for use in the monitoring and management of patients who are prescribed CNS stimulant medications.